PMID- 35887981
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 14
DP  - 2022 Jul 20
TI  - TNF-alpha Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan 
      Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and 
      ADMA) in Women with Rheumatoid Arthritis.
LID - 10.3390/jcm11144213 [doi]
LID - 4213
AB  - Sulfated glycosaminoglycans (sGAGs) are likely to play an important role in the 
      development and progression of rheumatoid arthritis (RA)-associated 
      atherosclerosis. The present study investigated the effect of anti-tumor necrosis 
      factor-alpha (anti-TNF-alpha) therapy in combination with methotrexate on plasma sGAG 
      levels and serum markers of endothelial dysfunction. Among sGAG types, plasma 
      chondroitin/dermatan sulfate (CS/DS) and heparan sulfate/heparin (HS/H) were 
      characterized using electrophoretic fractionation. Serum levels of soluble 
      vascular cell adhesion molecule-1 (sVCAM-1), monocyte chemoattractant protein-1 
      (MCP-1), matrix metalloproteinase-9 (MMP-9) and asymmetric dimethylarginine 
      (ADMA) were measured by immunoassays. The measurements were carried out four 
      times: at baseline and after 3, 9 and 15 months of anti-TNF-alpha therapy. All 
      analyzed parameters, excluding ADMA, were significantly elevated in patients with 
      RA before the implementation of biological therapy compared to healthy subjects. 
      Performed anti-TNF-alpha treatment led to a successive decrease in HS/H levels toward 
      normal values, without any effect on CS/DS levels in female RA patients. The 
      treatment was also effective at lowering the serum levels of sVCAM-1, MCP-1, 
      MMP-9 and ADMA. Moreover, a significant positive correlation was found between 
      the circulating HS/H and the 28 joint disease activity score based on the 
      erythrocyte sedimentation rate (DAS28-ESR, r = 0.408; p <0.05), MCP-1 (r = 0.398; 
      p <0.05) and ADMA (r = 0.396; p <0.05) in patients before the first dose of TNF-alpha 
      inhibitor. In conclusion, a beneficial effect of anti-TNF-alpha therapy on 
      cell-surface heparan sulfate proteoglycans (HSPGs)/HS turnover and endothelial 
      dysfunction was observed in this study. This was manifested by a decrease in 
      blood HS/H levels and markers of endothelial activation, respectively. Moreover, 
      the decrease in the concentration of HS/H in the blood of patients during 
      treatment, progressing with the decline in disease activity, indicates that the 
      plasma HS/H profile may be useful for monitoring the efficacy of anti-TNF-alpha 
      treatment in patients with RA.
FAU - Szeremeta, Anna
AU  - Szeremeta A
AUID- ORCID: 0000-0001-8445-2490
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jednosci 8, 
      41-200 Sosnowiec, Poland.
FAU - Jura-Poltorak, Agnieszka
AU  - Jura-Poltorak A
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jednosci 8, 
      41-200 Sosnowiec, Poland.
FAU - Zon-Giebel, Aleksandra
AU  - Zon-Giebel A
AD  - Department of Rheumatology and Rehabilitation, Specialty Hospital No. 1, 
      Zeromskiego 7, 41-902 Bytom, Poland.
FAU - Olczyk, Krystyna
AU  - Olczyk K
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jednosci 8, 
      41-200 Sosnowiec, Poland.
FAU - Komosinska-Vassev, Katarzyna
AU  - Komosinska-Vassev K
AUID- ORCID: 0000-0003-2307-5884
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jednosci 8, 
      41-200 Sosnowiec, Poland.
LA  - eng
GR  - PCN-2-064/K/1/I/Medical University of Silesia/
GR  - 2013/09/N/NZ5/00815/The National Science Centre, Poland/
PT  - Journal Article
DEP - 20220720
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9320287
OTO - NOTNLM
OT  - ADMA
OT  - MCP-1
OT  - MMP-9
OT  - anti-TNF-alpha treatment
OT  - heparan sulfate/heparin
OT  - rheumatoid arthritis
OT  - sVCAM-1
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
PMCR- 2022/07/20
CRDT- 2022/07/27 01:27
PHST- 2022/06/06 00:00 [received]
PHST- 2022/07/13 00:00 [revised]
PHST- 2022/07/19 00:00 [accepted]
PHST- 2022/07/27 01:27 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
PHST- 2022/07/20 00:00 [pmc-release]
AID - jcm11144213 [pii]
AID - jcm-11-04213 [pii]
AID - 10.3390/jcm11144213 [doi]
PST - epublish
SO  - J Clin Med. 2022 Jul 20;11(14):4213. doi: 10.3390/jcm11144213.